Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer.
Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer.
复制标题
DOI：
10.1158/1535-7163.mct-15-0601
复制
发表时间：
2016-01
影响因子：
5.7
通讯作者：
DeLisi C
中科院分区：
文献类型：
--
作者：
Liu Y;Hu Z;DeLisi C
乳腺癌手术后的辅助治疗通常包括一个疗程的化疗（如果癌症缺乏激素受体）或一个疗程的激素治疗（否则）。在这里，我们报告了佐剂策略和突变途径模式之间的相关性。特别是我们发现，对于乳腺癌患者，在化疗组中富含非同义突变的途径与激素治疗组不同。我们应用最近开发的方法，确定协作通路组激素和化疗患者。一组协作的通路是其中每个成员在相同的通常是大量的样品中被改变的通路。具体地，我们发现以下：（i）由3种途径组成的化疗组和由20种途径组成的激素治疗组，两组的成员是相互排斥的。(ii)每一组都高度富集了乳腺癌的驱动因素。(iii)通路组与基于亚型的治疗建议相关。这些结果表明，使用这些途径组进行患者分析可能有助于制定个性化治疗计划，这些计划可能比目前可用的计划更准确和具体。
Adjuvant therapy following breast cancer surgery generally consists of either a course of chemotherapy if the cancer lacks hormone receptors, or a course of hormonal therapy, otherwise. Here we report a correlation between adjuvant strategy, and mutated pathway patterns. In particular we find that for breast cancer patients, pathways enriched in non-synonymous mutations in the chemotherapy group, are distinct from those of the hormonal therapy group. We apply a recently developed method that identifies collaborative pathway groups for hormone and chemotherapy patients. A collaborative group of pathways is one in which each member is altered in the same–generally large–number of samples. In particular we find the following: (i) A chemotherapy group consisting of 3 pathways and a hormone therapy group consisting of 20, the members of the two groups being mutually exclusive. (ii) Each group is highly enriched in breast cancer drivers. (iii) The pathway groups are correlates of subtype-based therapeutic recommendations. These results suggest that patient profiling using these pathway groups can potentially enable the development of personalized treatment plans that may be more accurate and specific than those currently available.